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Available online 22 October 2016AbstractPurpose: This study was to create and validate a new therapeutic strategy which can guild clinicians to select the optimal therapy for pa-
tients with spinal cord compression resulted from metastatic cancers.
Methods: The entire cohort of 206 consecutive patients was randomly divided into two groups: a training group and a validation group. For
the patients randomized to the training group, we retrospectively analyzed 12 preoperative factors. The receiver operating characteristic
(ROC) curve c-statistics were calculated to measure the capability of the score and the revised Tokuhashi score in the validation group.
Results: Four prognostic factors, primary site (P < 0.01), preoperative ambulatory status (P ¼ 0.02), visceral metastases (P < 0.01), and pre-
operative chemotherapy (P ¼ 0.04), were included in the scoring model. The prognostic scores ranged between 0 and 9 points, and three prog-
nostic groups were designed. The median survival were 3.4 months for patients with 0e2 points, 7.2 months for those with 3e5 points, and
18.3 months for those with 6e9 points, respectively (P< 0.01). In the validation group, the corresponding median survival was 3.8 months, 7.1
months, and 16.3 months, respectively (P< 0.01). The ROC curve c-statistics for the scores as a predictor of 3, 6, and 12 months survival rates
were 0.74, 0.78, and 0.83 respectively, and the c-statistics for the revised Tokuhashi scores were 0.73, 0.75, and 0.75, respectively.
Conclusions: We created and validated a new scoring model for predicting survival and function outcome of patients with spinal cord
compression resulted from metastatic cancers after surgical decompression. This scoring model can help select the optimal therapy for those
patients.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Metastatic epidural spinal cord compression (MESCC)
is an oncologic emergency and occurs in approximately
5e10% of advanced cancer patients, which, unless earlySCC, Metastatic epidural spinal cord compression;
l survival; m, months; HR, hazard ratio; CI, confi-
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).diagnosed and timely treated (within 48 h), can lead to per-
manent neurologic deficits and seriously affect patient’s
quality of remaining life.1e3 Opinions regarding the aggres-
siveness of the interventions to be used in this palliative
context are polarized, since the most optimal treatment
for MESCC are still controversial. In 2005, a prospective
randomized trial strongly showed that decompressive sur-
gery followed by radiotherapy was superior to radiotherapy
alone.4,5 Recently, a meta-analysis also indicated that direct
decompressive surgery followed by radiotherapy may pro-
duce better clinical improvement of ambulation status and
survival than radiotherapy alone in 2014.6 Generally
speaking, decompressive surgery become the standardcess article under the CC BY-NC-ND license (http://creativecommons.org/
1925M. Lei et al. / EJSO 42 (2016) 1924e1930method in the treatment of MESCC, but optimal therapeu-
tic strategies in MESCC patients still rely on accurate pa-
tient selection. Such selection should take into account
patient’s survival prognosis and function outcome, which
can be evaluated with the prognostic scores.
Previously, we proposed scoring systems to enable phy-
sicians to identify patients with MESCC who may be the
best candidates for decompressive surgery, supportive
care alone, or more aggressive surgery.7e9 However, those
scoring models were especially for lung cancer or non-
small cell lung cancer patients. We also have developed a
scoring model according to the survival and functional
prognosis in MESCC patients from various cancer pa-
tients,10 while this scoring model was not validated, and
one may consider five prognostic characteristic too compli-
cated for daily routine.
Several other scoring models were developed to estimate
the survival outcome of each patient and select the optimal
treatment strategies.11e17 However, the predictive accuracy
of life expectancy with these traditional and commonly-
used scoring models was relatively inaccurate because of
the increase in survival induced by anti-cancer agents,
such as molecularly targeted interventions and other adju-
vant therapies, in recent years.17e21 Moreover, function sta-
tus plays an important role in advanced cancer patient’s
quality of remaining life, so this should be directly consid-
ered in the scoring model. Therefore, our present study was
initiated to create and validate a survival scoring model and
analyze function prognosis for MESCC patients from
various primary cancers after decompressive surgery and
spine stabilization.
Materials and methodsPatientsWe retrospectively analyzed patients with MESCC who
were operated with decompressive surgery between May
2005 and September 2015. The diagnosis of bone metas-
tasis was histologically confirmed, and MESCC was proved
by MRI. MESCC is radiographically defined as epidural
metastatic lesion(s) leading to true displacement of the spi-
nal cord from its normal position. Patients who were too
poor to undergo surgery were not included. Patients with
intradural metastasis or pathological fracture in the extrem-
ities were also excluded. Patients who had surgery for mul-
tiple MESCC (more than one site) at the same time were
included. This retrospective study was proved by the Med-
ical Research Ethics Board of the Affiliated Hospital of
Academy of Military Medical Sciences.Survival analysisThe entire cohort of patients was randomly assigned
to a training group and a validation group. For patients
randomized to the training group, we retrospectivelyanalyzed twelve preoperative characteristics for postop-
erative survival, including age (56 years vs. >56 years;
median age: 56 years), gender (female vs. male), pri-
mary site (slow growth vs. moderate growth vs. rapid
growth), preoperative ambulatory status (ambulatory vs.
not ambulatory), Eastern Cooperative Oncology Group
(ECOG) performance status (1e2 vs. 3e4), number of
involved vertebrae (1e2 vs. 3, conformed to previous
studies), visceral metastases (no vs. yes), preoperative
chemotherapy (no vs. yes), bone metastasis at cancer
diagnosis (no vs. yes), the time developing motor defi-
cits (14 days vs. >14 days, median time: 14 days9),
preoperative albumin (35 g/l vs. >35 g/l, conformed
to previous studies), and radical surgery at primary
site (no vs. yes).
Primary cancer was classified into three groups based
on biological behavior22: rapid growth group (48 cases
in the training group), including lung cancer without
molecularly targeted drugs (30 cases), colorectal cancer
(4 cases), esophageal cancer (4 cases), hepatocellular car-
cinoma (2 cases), head and neck cancer (1 case), mela-
noma (1 case), malignant thymoma (1 case), gastric
cancer (0), pancreatic cancer (0), and cancers of unknown
origin (5 case), moderate growth group (35 cases in the
training group), including lung cancer treated with molec-
ularly targeted drugs (18 cases), hormone-independent
breast cancer (8 cases), hormone-independent prostate
cancer (1 case), renal cell carcinoma (5 cases), endome-
trial cancer (1 case), ovarian cancer (1 case), and sarcoma
(1 case), or slow growth group (20 cases in the training
group), including hormone-dependent breast cancer (12
cases), hormone-dependent prostate cancer (1 case), thy-
roid cancer (4 cases), multiple myeloma (2 cases), and
malignant lymphoma (1 case). The postoperative survival
was defined as the period between the date of operation
and death or the latest follow-up, and patients who were
alive at the last follow-up were censored in the postoper-
ative survival analysis. When we initially designed this
study, visceral metastasis was recorded as being present
or not present. In the analysis of the c-statistics for the
revised Tokuhashi score, if the patients presented with
visceral metastasis, they were regarded as “non-
removable”.Surgery and function analysisThe indication for surgery was neurological deficit due
to MESCC. Patients were performed with posterior surgical
decompression and spine stabilization. Radiotherapy,
chemotherapy, or other adjuvant therapies, such as endo-
crine therapy and targeted therapy, were routinely per-
formed after the wound healed, approximately 3e4 weeks
after the operation. Postoperative function outcome was
also analyzed according to the scoring model. Neurological
function was graded according to Frankel grades before
operation and 4 weeks after operation.
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groups were compared by Chi-square test. The univariate
and multivariate analysis of postoperative survival in the
training group were estimated by the simple and multiple
Cox proportional hazards regression models, respectively.
In the multivariate analysis of the training group, we
included the significant characteristics for postoperative
survival in the scoring model. The scoring point for each
significant factor was obtained from the hazard ratios on
multiple Cox proportional hazards regression model. The
total prognostic score of each patient was the sum of all
the scores from the significant prognostic characteristics.
In the validation group, ROC curves were used to calculate
the accuracy and c-statistic of the scoring model and the
revised Tokuhashi scoring model for predicting 3, 6, and
12 months survival rates. The c statistic which is equivalent
to the area under ROC curve is the probability of concor-
dance between predicted and observed survival, with a
value of 0.7e0.8 representing a useful scoring model and
a value of more than 0.8 indicating a good scoring model.
Regarding postoperative function outcome, the correlations
between prognostic groups and postoperative neurological
status were determined by Spearman rank correlation
both in the training and the validation groups, and the
ambulatory status in prognostic groups were compared
with Chi-square test. Statistical significance was deter-
mined as P < 0.05, and statistical analysis was carried
out using SAS 9.2 software.
ResultsPatient characteristicsA cohort of two hundred and six patients was included in
the study. The entire cohort of patients was randomly as-
signed to a training group (n ¼ 103) and a validation group
(n ¼ 103). In the training group, the median overall survival
was 7.9 months (95% CI, 5.6e10.9 months), 6-month sur-
vival was 57.6%, and 1-year survival rate was 35.6%. As
for the validation group, the median overall survival was
7.1 months (95% CI, 6.3e9.0 months), 6-month survival
rate was 61.8%, and 1-year survival rate was 30.1%. During
the latest follow-up, twelve patients were alive in the
training group with a median follow-up of 5.2 months
(95% CI, 2.7e30.0 months). The characteristics related to
both groups were summarized in Supplementary Table 1,
and it revealed that the distribution of each characteristic
was similar.Creation of a scoring modelIn the univariate analysis of postoperative survival, pri-
mary site (HR, 1.96, 95% CI: 1.46e2.63; P < 0.01), preop-
erative ambulatory status (HR, 1.60, 95% CI: 1.04e2.47;P ¼ 0.03), visceral metastases (HR, 2.51, 95% CI:
1.62e3.90; P < 0.01), preoperative chemotherapy (HR,
2.70, 95% CI: 1.66e4.40; P < 0.01), bone metastasis at
cancer diagnosis (HR, 1.66, 95% CI: 1.06e2.58;
P ¼ 0.03), and radical surgery at primary site (HR, 2.28,
95% CI: 1.40e3.72; P < 0.01) were significant in the
training group (Table 1). Of the above six potential prog-
nostic factors, four were significantly associated with post-
operative survival according to the multiple Cox
proportional hazards regression model. These four signifi-
cant characteristics were as follows: primary site (HR,
1.67, 95% CI: 1.22e2.27; P < 0.01), preoperative ambula-
tory status (HR, 1.67, 95% CI: 1.06e2.64; P ¼ 0.02),
visceral metastases (HR, 2.53, 95% CI: 1.59e4.02;
P < 0.01), and preoperative chemotherapy (HR, 1.73,
95% CI: 1.01e2.97; P ¼ 0.04) (Table 1). The scoring
points for each of the four significant characteristics ob-
tained from the hazard ratios (rounded values) were seen
in Table 2. The total prognostic score of each patient was
the sum of all the scores from the four significant prog-
nostic characteristics. The sum resulted in prognostic scores
of 0e9 points. Taking into account the 6-month survival
rate and median survival time of each prognostic score,
the patients of the training group were divided into three
prognostic groups: 0e2 points (group A, n ¼ 30), 3e5
points (Group B, n ¼ 40), and 6e9 points (group C,
n ¼ 33). The corresponding median survival were 3.4
months (95% CI, 2.7e4.5 months), 7.2 months (95% CI,
5.5e10.9 months), and 18.3 months (95% CI, 11.7e21.4
months), respectively, and the 6-month survival rates
were 15.2%, 60.7%, and 90.9%, respectively (P < 0.01,
Fig. S1).
Regarding postoperative function outcome, there was
correlation between prognostic groups and postoperative
neurological status in the training group (P < 0.01, Table
3), which indicated that the lower score the patients had,
the poorer postoperative function outcome the patients suf-
fered. In the training group, the postoperative ambulatory
rates were 36.7% (11/30) in patients with 0e2 points,
85.0% (34/40) in patients with 3e5 points, and 97.0%
(32/33) in patients with 6e9 points, respectively
(P < 0.01). In the entire cohort of 103 patients in the
training group, 74.8% (77/103) patients had the ability to
walk after surgery, 60.0% (27/45) of nonambulatory pa-
tients before operation became ambulatory after surgery,
and 86.2% (50/58) of ambulatory patients maintained their
neurological status.Validation of the scoring modelAccording to the scoring model, the corresponding me-
dian survival of the three prognostic groups in the valida-
tion group were 3.8 months (95% CI, 2.2e4.8 months) in
group A (n ¼ 24), 7.1 months (95% CI, 6.3e10.2 months)
in group B (n ¼ 50), and 16.3 months (95% CI, 13.6e26.0
months) in group C (n ¼ 29), and the 6-month survival
Table 1
Training group: univariate and multivariate analysis of preoperative factors for postoperative survival in patients with MESCC.
Characteristics Patients (n) MOS (m) Simple Cox regression Multiple Cox regression
HR (95% CI) P HR (95% CI) P
Age
56 years 52 10.6 1.13 (0.73e1.74) 0.58 Not included
>56 years 51 7.1
Gender
Female 55 8.2 1.03 (0.67e1.60) 0.89 Not included
Male 48 7.9
Primary site
Slow growth 20 20.6 1.96 (1.46e2.63) <0.01 1.67 (1.22e2.27) <0.01
Moderate growth 35 8.8
Rapid growth 48 4.8
Preoperative ambulatory status
Ambulatory 58 10.8 1.60 (1.04e2.47) 0.03 1.67 (1.06e2.64) 0.02
Not ambulatory 45 7.1
ECOG performance status
1e2 54 10.8 1.36 (0.88e2.10) 0.16 Not included
3e4 49 5.6
Number of involved vertebrae
1e2 58 10.8 1.12 (0.72e1.73) 0.62 Not included
3 45 7.2
Visceral metastases
No 54 12.8 2.51 (1.62e3.90) <0.01 2.53 (1.59e4.02) <0.01
Yes 49 4.3
Preoperative chemotherapy
No 64 5.6 2.70 (1.66e4.40) <0.01 1.73 (1.01e2.97) 0.04
Yes 39 14.3
Bone metastasis at cancer diagnosis
No 49 10.9 1.66 (1.06e2.58) 0.03 Not included
Yes 54 6.6
Time developing motor deficits
14 days 52 6.0 1.46 (0.94e2.25) 0.09 Not included
>14 days 51 10.8
Preoperative albumin
35 g/l 46 9.1 1.03 (0.67e1.59) 0.89 Not included
>35 g/l 57 7.2
Radical surgery at primary site
No 68 6.0 2.28 (1.40e3.72) <0.01 Not included
Yes 35 14.3
Abbreviations: MESCC, Metastatic epidural spinal cord compression; MOS, median overall survival; m, months; HR, hazard ratio; CI, confidence interval;
ECOG, Eastern Cooperative Oncology Group.
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(P < 0.01, Fig. S2). In the validation group, the ROC curve
c-statistic for the scores as a predictor of 3 months survival
rate was 0.74, c-statistic as a predictor of 6 months survival
rate was 0.78, and c-statistic as a predictor of 12 months
survival rate was 0.83 (Fig. 1 and Fig. S3e4). The accuracy
rates for predicting 3, 6, and 12 months survival were
68.5%, 72.7%, and 79.1%, respectively. The predicted
and observed survival rates of 3, 6, and 12 months were
shown in Fig. 2 and Fig. S5e6. The ROC curve c-statistics
for the revised Tokuhashi scores as a predictor of 3 months,
6 months, and 12 months survival rate were 0.73, 0.75, and
0.75, respectively (Fig. S7e9). The accuracy rates for pre-
dicting 3, 6, and 12 months survival were 68.9%, 71.6%,
and 71.3%, respectively.
As for function outcome, there was also correlation be-
tween prognostic groups and postoperative neurologicalstatus in the validation group (Table 3). In details, the
ambulatory rates were 37.5% (9/24) in patients with 0e2
points, 78.0% (39/50) in patients with 3e5 points, and
93.1% (27/29) in patients with 6e9 points, respectively
(P < 0.01).
Discussion
Prediction of survival for patients with metastatic spinal
disease holds extremely importance, since patients selec-
tion largely depends on their survival and function prog-
nosis. Generally speaking, patients with very poor
survival and function outcome seem to be well treated
with radiotherapy or even best supportive cares, while pa-
tients with a favorable survival outcome (expected survival
time was greater than 3e6 months1,11,13) and function prog-
nosis may be potential candidates for decompressive
Table 2
A new validated scoring model for patients with MESCC after decompres-
sive surgery.
Prognostic factors Scores
Primary site
Slow growth 2
Moderate growth 1
Rapid growth 0
Preoperative ambulatory status
Ambulatory 2
Not ambulatory 0
Visceral metastases
No 3
Yes 0
Preoperative chemotherapy
No 0
Yes 2
Prognostic groups
Group A 0e2
Group B 3e5
Group C 6e9
Abbreviations: MESCC, Metastatic epidural spinal cord compression.
Slow growth: hormone-dependent breast cancer, hormone-dependent pros-
tate cancer, thyroid cancer, multiple myeloma, and malignant lymphoma.
Moderate growth: lung cancer treated with molecularly targeted drugs,
hormone-independent breast cancer, hormone-independent prostate cancer,
renal cell carcinoma, endometrial cancer, ovarian cancer, and sarcoma.
Rapid growth: lung cancer without molecularly targeted drugs, colorectal
cancer, gastric cancer, pancreatic cancer, esophageal cancer, other urologi-
cal cancers, hepatocellular carcinoma, head and neck cancer, melanoma,
malignant thymoma and cancers of unknown origin.
Table 3
Training and validation groups: neurological recovery of the patient in
prognostic groups 4 weeks after surgery.
Groups Prognostic
groups
Patients (n) Neurological status
according to
Frankel grades
P
A B C D E
Training A 30 3 6 10 8 3 P1 < 0.01
B 40 0 2 4 19 15
C 33 0 0 1 9 23
Validation A 24 2 5 8 7 2 P2 < 0.01
B 50 1 3 7 21 18
C 29 0 1 1 10 17
P1 and P2: The correlations between prognostic groups and neurological
status in the test and validation groups, respectively, which were obtained
from the Spearman rank correlation.
1928 M. Lei et al. / EJSO 42 (2016) 1924e1930surgery. In contrast, patients with the excellent survival and
function outcome should be treated with more aggressive
surgery, such as excisional procedures, which may facilitate
better local control of disease.
Several scoring models have been designed for predict-
ing survival prognosis in patient with spinal metastasis.
The most commonly-used scoring models were Tokuhashi
score (1990),11 revised Tokuhashi score (2005),12 Tomita
score (2001),13 Van der Linden score (2005),14 Sioutos
score (1995),15 Bauer score (1995),16 and Bauer modified
score.17 However, the assessment of the available scores ismandatory to test their current availability and validity.
Leithner et al.17 evaluated the accuracy of the above seven
preoperative prognostic scoring models in a series of 69 pa-
tients, and the data emphasized that only the Bauer score
and Bauer modified score seemed to be practicable and pre-
dictable for patients with spinal metastasis. Tabouret et al.18
assessed the precision of Tomita and Tokuhashi scores in
patients with malignancies associated with MESCC in a
cohort of 148 patients and concluded that only Tokuhashi
score was relevant, but the predictive accuracy of survival
was just 51%. Yu et al.19 showed that the Tokuhashi score
was not a reliable tool to predict survival in patients with
spinal metastases from lung cancer, as only 8.6% patients
actually followed the survivorship pattern as predicted by
the Tokuhashi score. To our knowledge, those prognostic
scores were proposed in the 1990s or early 2000s, but the
majority of the recent anti-cancer targeted agents were
available from 2005. Thanks to the development of molec-
ularly targeted interventions and other adjuvant therapies,
patients with MESCC are living longer, especially in pulmo-
nary and renal cancers patients.23 The underestimation of
expected survival and subsequent inadequate treatment of
MESCC may lead to dramatic loss of the patient’s quality
of remaining life. Therefore, new scoring models consid-
ering the increase in survival induced by anti-cancer agents
in recent years is really needed. In 2016, Bartels et al.24 pro-
spectively validated the scoring model which contained five
prognostic factors: sex, location of the primary lesion, inten-
tional curative treatment of the primary tumor, cervical loca-
tion of the spinal metastasis, and KPS, finding that the
prediction model’s overall performance was good in the re-
cords of 110 patients. The authors declared that this model
can help doctors to identify surgical candidates. However, a
matched pair analysis didn’t find any significant difference
in survival between the cervical spine metastasis and the
thoracic or lumbar spine metastasis.21 Thus, whether the
location of the spinal metastasis was significantly associated
with survival need further investigations.
In the present study, the scoring model was proposed ac-
cording to the data derived from 206 patients with MESCC
who were treated with surgical decompression and spine
stabilization. Primary cancers were classified into three
groups, namely, tumors that exhibited rapid growth, such
as lung cancer without molecularly targeted drugs, moder-
ate growth, such as lung cancer treated with molecularly
targeted drugs and hormone-independent breast and pros-
tate cancer, and slow growth, such as hormone-dependent
breast and prostate cancer. The patient’s individual situation
relating to the recent anti-cancer agents is considered in the
present score. Moreover, a validation group was used to
confirm the scoring model. The prognostic groups of the
training group were compared to the corresponding groups
of the validation group: the 6-month survival rates and me-
dian survival time of the three prognostic groups in the vali-
dation group were proved to be similar to the corresponding
6-month survival rates and median survival time of the three
Figure 1. ROC curve for the prognostic scores as a predictor of 3 months
survival rate.
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that the scoring model appeared valid and reproducible.
Regarding function outcome after surgery, according to
the validated scoring model, we found that there was corre-
lation between prognostic groups and postoperative neuro-
logical status both in the training and validation groups,
which suggested that the lower score the patients had, the
poorer postoperative function outcome the patients sufferedFigure 2. The predicted and obserfrom. Besides, in the training group, the postoperative
ambulatory rates were 36.7% in patients with 0e2 points,
85.0% in patients with 3e5 points, and 97.0% in patients
with 6e9 points, respectively. As for validation group, the
corresponding ambulatory rates were 37.5%, 78.0%, and
93.1%, respectively. Thus, this scoring model can also be
treated as valid in terms of postoperative function outcome.
In the validation group, the ROC curve c-statistic for the
scores as a predictor of 3 months survival rate was 0.74,
c-statistic as a predictor of 6 months survival rate was
0.78, and c-statistic as a predictor of 12 months survival
rate was 0.83, which suggested that this scoring model
was a useful tool to predict survival prognosis. The ROC
curve c-statistics for the revised Tokuhashi scores as a pre-
dictor of 3 months, 6 months, and 12 months survival rate
were 0.73, 0.75, and 0.75, respectively. The c-statistics for
the revised Tokuhashi scores were relatively lower than
those for our scores, which indicated that our scoring sys-
tem was relatively better than the revised Tokuhashi scoring
system in predicting patient’s survival prognosis.
However, the therapeutic decision of patients with
MESCC should never base on a prognostic score alone.
To our knowledge, there is always patient’s hope for a treat-
ment that might preserve patient’s ambulatory function and
improve their quality of remaining life, although poor prog-
nosis predicted by some commonly-used prognostic scores.
Thus, patient’s individual intention should be respected.
Moreover, a hidden selection bias cannot be excluded
because the present scoring model was derived from retro-
spective data. Therefore, the scoring model still needs a
prospective study to be re-evaluated, despite positive pre-
dictive value.ved 3 months survival rates.
1930 M. Lei et al. / EJSO 42 (2016) 1924e1930In conclusion, because the survival rates, survival prog-
nosis, and postoperative function outcome of the validation
group were found to be similar to those of the training
group, this scoring model can be treated predictable and
valid. This scoring model can help select the personalized
therapy for patients with MESCC. Patients with scores of
0e2 points, who have the poorest survival prognosis (life
expectancy is about 3 months) and function outcome,
seem well treated with radiotherapy or supportive care. Pa-
tients with scores of 3e5 points may potentially benefit
from decompressive operation due to preferable survival
prognosis and function outcome after surgery, while pa-
tients with scores of 6e9 points, who have the most favor-
able survival prognosis and function outcome, can be
treated with more aggressive surgery, which can lead to bet-
ter control of local disease. This scoring model was a useful
model to predict survival and function prognosis and rela-
tively better than the revised Tokuhashi scoring model.
Still, the scoring model should be re-evaluated in a prospec-
tive trial. A multicenter prospective cohort study which is
registered at Chinese Clinical Trial Registry (ChiCTR-
POC-16008393) is underway.
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